NSABP FOUNDATION, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Employees
- -
- Market Cap
- -
Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 5351
- Registration Number
- NCT00003782
- Locations
- 🇺🇸
Comprehensive Cancer Institute, Huntsville, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸CCOP - Western Regional, Arizona, Phoenix, Arizona, United States
Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 1598
- Registration Number
- NCT00016432
- Locations
- 🇺🇸
Comprehensive Cancer Institute of Huntsville, Huntsville, Alabama, United States
🇺🇸CCOP - Greater Phoenix, Phoenix, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer
Phase 2
Completed
- Conditions
- Breast Neoplasms
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 33
- Registration Number
- NCT00052169
- Locations
- 🇺🇸
NSABP Operations Center, Pittsburgh, Pennsylvania, United States
Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 2130
- Registration Number
- NCT00004067
- Locations
- 🇺🇸
Comprehensive Cancer Institute, Huntsville, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸CCOP - Western Regional, Arizona, Phoenix, Arizona, United States
Tamoxifen Study
Phase 3
Completed
- Conditions
- Cardiovascular DiseasesCoronary DiseaseHeart DiseasesHypertensionMyocardial Ischemia
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- NSABP Foundation Inc
- Registration Number
- NCT00000529